Dr. P.J.W. Naudé
ZonMW | Alzheimer Nederland | Neurosearch Antwerp.
The Netherlands
Lipocalin 2 and its receptor, megalin, as diagnostic and drug targets in early stages of Alzheimers disease.
ZonMW | Alzheimer Nederland | Neurosearch Antwerp.
150,000
01/11/15
3.0
Alzheimer's disease & other dementias
Neuroinflammation | diagnostic markers | therapeutic target | mild cognitive impairment | Lipocalin 2 | Megalin | early Alzheimers disease
Lipocalin 2 (Lcn2) is a newly identified (neuro)inflammatory component that, together with its receptor, megalin, can play important roles in the pathophysiology of Alzheimers disease (AD) development. This project will investigate Lcn2 and megalin as novel diagnostic and therapeutic targets for early AD, addressing two fundamental research topics in this field: i.e. early diagnosis and early intervention, aiming to prevent AD development or at least stop or slow down disease progression.